GH-axis research
Sermorelin
Peptide lyophilisé de recherche de signalisation endocrinienne pour l'examen des systèmes
Sermorelin is a GHRH 1-29 analog studied as a classic pituitary GH-axis research reference.
Support can confirm any currently available COAs or batch documentation for this product.
Request available documentsConfirm an optional email signup to receive a single-use 10% welcome code.
Get catalog updatesPour la recherche en laboratoire uniquement. Pas pour un usage humain ou vétérinaire. Non destiné à diagnostiquer, traiter, guérir, atténuer ou prévenir une maladie.
Conserver scellé, froid, sec et protégé des variations de chaleur. Confirmez le stockage spécifique au produit à l'arrivée.
Emballé pour la stabilité du transit avec une assistance aux commandes disponible pour les itinéraires par temps chaud.
Batch-linked certificate support is available through the documentation desk.
Contexte de recherche
Profil de recherche Sermorelin
Sermorelin is a 29-amino-acid analog corresponding to the active amino-terminal region of growth hormone-releasing hormone. It is used as a classic reference for pituitary GHRH-receptor signaling, stimulated GH release, endocrine responsiveness, and downstream IGF-1 measurements. Compared with CJC-1295 with DAC, sermorelin represents a shorter GHRH framework without the same half-life-extension design. Compared with ipamorelin and GHRP peptides, it acts through a different receptor pathway. Researchers generally select sermorelin when the study calls for a well-established GHRH 1-29 reference or a direct comparison of pituitary signaling across GHRH analogs and ghrelin-receptor secretagogues.
Molecular class
44-residue GHRH 1-44 analog
Sequence / composition
A synthetic amino-terminal 44-residue segment corresponding to the receptor-active region of human GHRH.
Research design note
It is a direct GHRH-receptor reference, unlike GH secretagogues that act through GHS-R.
Mécanisme proposé
A synthetic GHRH(1-29) peptide that activates the pituitary GHRH receptor, increases cyclic AMP, and stimulates endogenous growth-hormone release from responsive somatotroph cells.
Effets rapportés dans les études
- Human diagnostic and pharmacology studies reported acute GH release and used the response to evaluate pituitary reserve.
- Downstream changes can include transient increases in GH and IGF-1-related markers when repeated exposure is studied.
- Responses vary with age, pituitary function, endogenous somatostatin tone, timing, and prior exposure.
Critères de recherche courants
GHRH receptor signaling, cyclic AMP, peak and integrated GH, IGF-1, pituitary responsiveness, age-related response, pharmacokinetics, and comparison with longer-acting GHRH analogs.
Preuves et limites
The GHRH stimulation mechanism is well characterized, including historical human diagnostic use. This does not establish therapeutic equivalence of a catalog product.
External reading
Literature for context—not product proof.
Third-party sources describe their own research materials and methods. They do not validate a specific Azure catalog batch.
Support and documentation
Questions about this product?
Where can I find product documentation?
Contact support with the product name and any relevant order or batch reference to request available documents.
How can I compare pack options?
Where multiple pack sizes are available, Azure shows the price per listed vial so you can compare catalog value directly.